Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children

University Hospital, Clermont-Ferrand

Status: Unknown

Conditions: Benign Disease

Study type: Observational

Funder types: Other

Identifiers

NCT00751452

CHU-0040

Details and patient eligibility

About

determine the interest of the dosage of citrullinemia to monitor the bowel damage after allogeneic bone marrow transplantation in children.

Full description

30 children included. Dosage of citrullinemia on day -7, day 0 and every week up to 100 days after BMT. Histological examination and extensive infectious screening in case of persistent digestive symptoms (more than 3 days).

Two groups of patients regarding on digestive involvement. Comparison of the values of citrullinemia between these two groups.

Enrollment: 30 estimated patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 0 to 18 years
• allogeneic bone marrow transplantation for malignant or benign disease
• affiliation to French sécurité sociale
• parent's consent

Exclusion criteria

• severe gastro-intestinal involvement before transplant
• previous digestive surgery

Trial design

30 participants in 2 patient groups

1

2